Day: May 9, 2024

CALGARY, Alberta, May 09, 2024 (GLOBE NEWSWIRE) — Total Energy Services Inc. (“Total Energy” or the “Company”) (TSX:TOT) announces its consolidated financial results for the three months ended March 31, 2024. Financial Highlights ($000’s except per share data)   Three months endedMarch 31     2024     2023   Change Revenue $ 204,686   $ 237,777   (14 %) Operating income   22,030     28,020   (21 %) EBITDA (1)   43,290     48,475   (11 %) Cashflow   32,837     48,672   (33 %) Net income   15,463     24,038   (36 %) Attributable to shareholders   15,482     24,040   (36 %)                 Per Share Data (Diluted)               EBITDA (1) $ 1.06   $ 1.15   (8 %) Cashflow $ 0.80   $ 1.16   (31 %)                 Attributable to shareholders:               Net income $ 0.38   $ 0.57   (33 %)                 Common...

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, May 09, 2024 (GLOBE NEWSWIRE) — NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a growing home health care organization, is pleased to announce the release of financial results for the quarter ended March 31, 2024. All amounts are in United States dollars unless otherwise specified. Nova Leap Q1 2024 Financial Results Financial results for the first quarter ended March 31, 2024 include the following: Q1 2024 revenues of $6,429,721 decreased by 1.9% relative to Q4 2023 revenues of $6,551,865 and were higher than Q1 2023 revenues of $6,396,076 by 0.5%. Q1 2024 Adjusted EBITDA of $361,802 was a decrease of 36.7% over Q4 2023 Adjusted EBITDA of $571,270 and an increase of 321% over Q1 2023 Adjusted...

CALGARY, Alberta, May 09, 2024 (GLOBE NEWSWIRE) — Inventronics Limited (“Corporation”) (IVX:TSX Venture), a designer and manufacturer of enclosures for the telecommunications, cable, electric distribution, energy, and other industries in North America, today announced its unaudited 2024 Q1 financial results. For the three months ended March 31, 2024, the Corporation reported net earnings of $8,000, or 0.2 cents per share, on revenue of $1,432,000 compared to net earnings of $325,000, or 6.7 cents per share, on revenue of $3,335,000 for the same period of 2023. The demand for enclosures has strengthened from the low levels experienced in the fourth quarter of 2023 as customers work their way through their excess inventories. Financial Highlights   Three months ended (in thousands of dollars, except per share amounts)   Mar 312024 Mar...

VANCOUVER, British Columbia, May 09, 2024 (GLOBE NEWSWIRE) — Diversified Royalty Corp. (TSX: DIV and DIV.DB.A) (the “Corporation” or “DIV”) is pleased to announce its financial results for the three months ended March 31, 2024 (“Q1 2024”). Highlights The weighted average organic royalty growth1 of DIV’s diversified royalty portfolio was 6.0% in Q1 2024, compared to 11.1% for the three months ended March 31, 2023 (“Q1 2023”). The weighted average organic royalty growth1 on a consistent currency basis was 6.0% in Q1 2024. Revenue was $15.1 million in Q1 2024, up 22.2%, compared to $12.3 million in Q1 2023. Adjusted revenue1 of $16.4 million in Q1 2024, up 20.3%, compared to $13.6 million in Q1 2023. Distributable cash1 of $9.6 million in Q1 2024, up 8.4%, compared to $8.8 million in Q1 2023. Payout ratio1 of 97.2% in Q1 2024 on...

BURR RIDGE, Ill., May 09, 2024 (GLOBE NEWSWIRE) — BankFinancial Corporation (Nasdaq – BFIN) (“BankFinancial”) filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, and a Quarterly Financial and Statistical Supplement in Form 8-K with the U.S. Securities and Exchange Commission (the “SEC”) today. BankFinancial reported net income for the three months ended March 31, 2024, of $1.7 million, or $0.14 per common share. At March 31, 2024, BankFinancial had total assets of $1.480 billion, total loans of $1.008 billion, total deposits of $1.259 billion and stockholders’ equity of $156 million. In the first quarter of 2024, interest income increased by $422,000 due to our investment of scheduled loan and lease portfolio payments into short-term liquidity investments.  Interest expense increased by $327,000...

Management Board of Northern Horizon Capital AS has approved the unaudited financial results of Baltic Horizon Fund (the Fund) for the three months of 2024. Our strategic ambitionsOver the past year, our focus has been on reshaping our strategy to foster sustainable value, concentrating efforts on avenues that promise reliable and consistent growth for our investors. In light of prevailing market conditions, we firmly believe that the execution of the ‘Modern City Life’ strategy, introduced to investors in summer 2023, is paramount to their best interests. In the coming years, we expect two thirds of the Fund’s NOI to come from centrally located multi-functional assets aligned with our ‘Modern City Life’ strategy. These spaces are meticulously designed to ignite, elevate and enrich the lives of modern citizens and communities. The remaining...

Management Board of Northern Horizon Capital AS has approved the unaudited financial results of Baltic Horizon Fund (the Fund) for the three months of 2024. Our strategic ambitionsOver the past year, our focus has been on reshaping our strategy to foster sustainable value, concentrating efforts on avenues that promise reliable and consistent growth for our investors. In light of prevailing market conditions, we firmly believe that the execution of the ‘Modern City Life’ strategy, introduced to investors in summer 2023, is paramount to their best interests. In the coming years, we expect two thirds of the Fund’s NOI to come from centrally located multi-functional assets aligned with our ‘Modern City Life’ strategy. These spaces are meticulously designed to ignite, elevate and enrich the lives of modern citizens and communities. The remaining...

HIGH POINT, N.C., May 09, 2024 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of type 1 diabetes (“T1D”), today reported financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate developments. “The first quarter of 2024 saw us reach several important milestones, which we believe position vTv well for continued execution of our corporate and clinical development strategy,” said Paul Sekhri, Chief Executive Officer of vTv. “The proceeds of the private placement we announced at the end of February are expected to fully fund the first Phase 3 study of cadisegliatin in patients with T1D, for which we expect to report top line data in the first...